Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.
Interventions
DRUGliraglutide
Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions. No treatment given.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol) * Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea) * Male or female, no age limitation
Exclusion criteria
* Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772 * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of AEs (adverse events) | Week 0-52 |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse reactions (ARs) | Week 0-52 |
| Change in HbA1c (glycosylated haemoglobin) | Week 0, week 52 |
Countries
Japan
Outcome results
None listed